Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Venetoclax in Combination with Conventional Chemotherapy for the Treatment of Pediatric Patients with Acute Myeloid Leukemia

Trial Status: active

This phase II trial tests how well venetoclax works in combination with standard chemotherapy in treating pediatric patients with acute myeloid leukemia (AML). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. The usual treatment for AML is a group of cancer-fighting drugs called chemotherapy. Chemotherapy drugs, like cytarabine, daunorubicin hydrochloride, fludarabine phosphate, idarubicin hydrochloride, mitoxantrone hydrochloride, and azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Etoposide is also a chemotherapy drug in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and deoxyribonucleic acid repair and may kill cancer cells. Adding venetoclax to conventional chemotherapy may kill more cancer cells than chemotherapy alone in pediatric patients with AML.